Archive · 19 Aug 2025
FDA Approves Weight Loss Drug Semaglutide for Liver Disease
The FDA has approved a drug called semaglutide, originally for weight loss, to treat a liver problem called MASH.
MASH happens when fat builds up in the liver, causing it to get inflamed and damaged.
Semaglutide helps by addressing problems like obesity and diabetes, which can lead to MASH.
A study showed that many people taking semaglutide saw their liver problem get better.
In India, MASH is a growing concern, especially among people with unhealthy lifestyles.
FDA approved semaglutide, a weight-loss drug, for metabolic associated steatohepatitis (MASH).
MASH is a severe form of non-alcoholic fatty liver disease, leading to liver inflammation and damage.
Semaglutide was initially approved in 2017 for diabetes and later for obesity and cardiovascular diseases.
A study showed 63% of semaglutide users saw MASH resolution without worsening liver scarring.
MASH affects 9-32% of India's population; a study showed high prevalence among IT employees.
- Who
- The US FDA approved semaglutide.
- What
- FDA approved semaglutide for the treatment of metabolic associated steatohepatitis (MASH).
- When
- Approval was announced recently.
- Where
- United States
- Why
- To treat metabolic associated steatohepatitis (MASH).
- Drug Name
- Semaglutide
- Approved for
- MASH
- MASH condition
- Metabolic associated steatohepatitis
- Initial Approval
- 2017 for Diabetes
- Trial Results
- 63% of participants saw MASH resolution.